newsfilter
← Latest News
GlobeNewswire·

Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

  • Solid Biosciences Inc. (Nasdaq: SLDB) announced participation in the 2026 Jefferies Global Healthcare Conference in London.
  • President & CEO Bo Cumbo will attend a fireside chat on Monday, November 16, 2026, at 2:30 p.m. GMT (9:30 a.m. ET).
  • A live webcast of the presentation will be available via a provided link, with a replay archived for 90 days on the company Events page.
  • Management members will hold one-on-one investor meetings during the conference.
  • The company is developing gene therapy candidates including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for CPVT, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
  • Solid Biosciences focuses on advancing genetic regulators and enabling technologies to improve gene therapy delivery across the industry.
  • Investor inquiries can be directed to Nicole Anderson at investors@solidbio.com.
  • Media inquiries should be directed to Amir Khan at Syneos Health via email or phone at (347) 249-0230.
Company
Solid Biosciences Inc.
Keywords
Nasdaq:SLDB, Solid Biosciences Inc.